Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2019-01-22
DOI
10.3389/fimmu.2019.00008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Engineering the immune system with particles, step-by-step
- (2018) B.G. De Geest MOLECULAR IMMUNOLOGY
- Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer
- (2018) Douglas G. McNeel et al. Oncotarget
- Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?
- (2018) Fei Tang et al. Cell and Bioscience
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer
- (2017) Nobuyuki Katakami et al. LUNG CANCER
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting
- (2017) K. Vermaelen et al. SEMINARS IN CANCER BIOLOGY
- Signalling strength determines proapoptotic functions of STING
- (2017) Muhammet F. Gulen et al. Nature Communications
- Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein
- (2017) Y. Maurice Morillon et al. Oncotarget
- Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity
- (2017) Daniel O. Villarreal et al. Oncotarget
- Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
- (2017) Christelle Remy-Ziller et al. Human Vaccines & Immunotherapeutics
- Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
- (2017) James L. Gulley et al. JNCI-Journal of the National Cancer Institute
- Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment
- (2017) Susanne M. Steggerda et al. Journal for ImmunoTherapy of Cancer
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
- (2016) J. M. Pitt et al. ANNALS OF ONCOLOGY
- Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy
- (2016) Ashley E. Mahne et al. CANCER RESEARCH
- Combining Epigenetic and Immunotherapy to Combat Cancer
- (2016) Katherine B. Chiappinelli et al. CANCER RESEARCH
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Vaccine adjuvants as potential cancer immunotherapeutics
- (2016) Burcu Temizoz et al. INTERNATIONAL IMMUNOLOGY
- Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma
- (2016) Sofie Wilgenhof et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study
- (2016) Jean-Louis Pujol et al. Journal of Thoracic Oncology
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
- (2016) Elisabeth Quoix et al. LANCET ONCOLOGY
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses
- (2016) Marij J. Welters et al. Science Translational Medicine
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours
- (2016) Lukasz Bialkowski et al. Scientific Reports
- Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
- (2016) Nicole E. Scharping et al. Cancer Immunology Research
- A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
- (2016) Akio Ohta Frontiers in Immunology
- Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses
- (2015) P. Mitchell et al. ANNALS OF ONCOLOGY
- A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
- (2015) Deepa K. Krishnadas et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting the tumor vasculature to enhance T cell activity
- (2015) Evripidis Lanitis et al. CURRENT OPINION IN IMMUNOLOGY
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
- (2015) G. Giaccone et al. EUROPEAN JOURNAL OF CANCER
- Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants
- (2015) Robyn Marty-Roix et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Therapeutic cancer vaccines
- (2015) Cornelis J.M. Melief et al. JOURNAL OF CLINICAL INVESTIGATION
- Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants
- (2015) Melissa C. Hanson et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors following Combination Therapy with Vaccine and Anti-PD-1 Antibody
- (2014) L. Karyampudi et al. CANCER RESEARCH
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- Inflammasome-Dependent and -Independent IL-18 Production Mediates Immunity to the ISCOMATRIX Adjuvant
- (2014) N. S. Wilson et al. JOURNAL OF IMMUNOLOGY
- Tumor Mouse Model Confirms MAGE-A3 Cancer Immunotherapeutic As an Efficient Inducer of Long-Lasting Anti-Tumoral Responses
- (2014) Catherine Gérard et al. PLoS One
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- (2014) P. Kvistborg et al. Science Translational Medicine
- STING Ligand c-di-GMP Improves Cancer Vaccination against Metastatic Breast Cancer
- (2014) D. Chandra et al. Cancer Immunology Research
- TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
- (2014) Hailing Lu Frontiers in Immunology
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid
- (2013) J. Conlon et al. JOURNAL OF IMMUNOLOGY
- Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer
- (2013) Satoshi Wada et al. Journal of Translational Medicine
- Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses
- (2012) Kentaro Sumida et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Metabolism of L-Arginine by Myeloid-Derived Suppressor Cells in Cancer: Mechanisms of T cell suppression and Therapeutic Perspectives
- (2012) Patrick Raber et al. IMMUNOLOGICAL INVESTIGATIONS
- Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
- (2012) Kenneth J. Pienta et al. INVESTIGATIONAL NEW DRUGS
- A GpC-Rich Oligonucleotide Acts on Plasmacytoid Dendritic Cells To Promote Immune Suppression
- (2012) C. Volpi et al. JOURNAL OF IMMUNOLOGY
- Whole Cell Vaccines—Past Progress and Future Strategies
- (2012) Bridget P. Keenan et al. SEMINARS IN ONCOLOGY
- Targeting the tumor mutanome for personalized vaccination therapy
- (2012) Sebastian Kreiter et al. OncoImmunology
- Outlining novel cellular adjuvant products for therapeutic vaccines against cancer
- (2011) Josianne Nitcheu Tefit et al. Expert Review of Vaccines
- Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer
- (2011) Govind Ragupathi et al. Expert Review of Vaccines
- IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
- (2011) Sid P. Kerkar et al. JOURNAL OF CLINICAL INVESTIGATION
- Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
- (2011) Elisabeth Quoix et al. LANCET ONCOLOGY
- Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant
- (2011) Rhea N. Coler et al. PLoS One
- B regulatory cells and the tumor-promoting actions of TNF- during squamous carcinogenesis
- (2011) T. Schioppa et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FcRγ Activation Regulates Inflammation-Associated Squamous Carcinogenesis
- (2010) Pauline Andreu et al. CANCER CELL
- 5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity
- (2010) J. Vincent et al. CANCER RESEARCH
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
- (2010) K. N. Kodumudi et al. CLINICAL CANCER RESEARCH
- Anti-inflammatory Triterpenoid Blocks Immune Suppressive Function of MDSCs and Improves Immune Response in Cancer
- (2010) S. Nagaraj et al. CLINICAL CANCER RESEARCH
- An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma
- (2010) Collin Jacobs et al. INTERNATIONAL JOURNAL OF CANCER
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- TLR-based immune adjuvants
- (2010) Folkert Steinhagen et al. VACCINE
- Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy
- (2009) S. J. Priceman et al. BLOOD
- Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
- (2009) T. Nicholaou et al. CLINICAL CANCER RESEARCH
- Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial
- (2009) C. L. Slingluff et al. CLINICAL CANCER RESEARCH
- TLR3-Stimulated Dendritic Cells Up-regulate B7-H1 Expression and Influence the Magnitude of CD8 T Cell Responses to Tumor Vaccination
- (2009) V. Pulko et al. JOURNAL OF IMMUNOLOGY
- AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity
- (2009) A. M. Didierlaurent et al. JOURNAL OF IMMUNOLOGY
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- (2008) Alessandro Testori et al. JOURNAL OF CLINICAL ONCOLOGY
- The Immune Tolerance of Cancer is Mediated by IDO That is Inhibited by COX-2 Inhibitors Through Regulatory T Cells
- (2008) Sung Yong Lee et al. JOURNAL OF IMMUNOTHERAPY
- An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial
- (2008) Christopher Wood et al. LANCET
- Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
- (2007) Ronald J Buckanovich et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search